ATE411017T1 - Verfahren zur beeinflussung neurologischer progression - Google Patents

Verfahren zur beeinflussung neurologischer progression

Info

Publication number
ATE411017T1
ATE411017T1 AT02799240T AT02799240T ATE411017T1 AT E411017 T1 ATE411017 T1 AT E411017T1 AT 02799240 T AT02799240 T AT 02799240T AT 02799240 T AT02799240 T AT 02799240T AT E411017 T1 ATE411017 T1 AT E411017T1
Authority
AT
Austria
Prior art keywords
influencing
neurological progression
brain
neurological
progression
Prior art date
Application number
AT02799240T
Other languages
English (en)
Inventor
Richard Miller
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Application granted granted Critical
Publication of ATE411017T1 publication Critical patent/ATE411017T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • A61K47/546Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT02799240T 2001-12-13 2002-12-12 Verfahren zur beeinflussung neurologischer progression ATE411017T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33965001P 2001-12-13 2001-12-13
US34658402P 2002-01-07 2002-01-07
US35309002P 2002-01-30 2002-01-30

Publications (1)

Publication Number Publication Date
ATE411017T1 true ATE411017T1 (de) 2008-10-15

Family

ID=27407352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02799240T ATE411017T1 (de) 2001-12-13 2002-12-12 Verfahren zur beeinflussung neurologischer progression

Country Status (16)

Country Link
US (1) US20030130252A1 (de)
EP (1) EP1465617B1 (de)
JP (1) JP2005511719A (de)
KR (1) KR20040075001A (de)
CN (1) CN1615129A (de)
AT (1) ATE411017T1 (de)
AU (1) AU2002364165B2 (de)
CA (1) CA2469613A1 (de)
DE (1) DE60229437D1 (de)
DK (1) DK1465617T3 (de)
ES (1) ES2315429T3 (de)
IL (1) IL162469A0 (de)
MX (1) MXPA04005715A (de)
PL (1) PL372326A1 (de)
PT (1) PT1465617E (de)
WO (1) WO2003049731A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006206398A1 (en) * 2005-01-19 2006-07-27 Pharmacyclics, Inc. A method for treating neurologic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Also Published As

Publication number Publication date
EP1465617A1 (de) 2004-10-13
US20030130252A1 (en) 2003-07-10
AU2002364165B2 (en) 2007-09-20
CA2469613A1 (en) 2003-06-19
PT1465617E (pt) 2009-01-23
KR20040075001A (ko) 2004-08-26
DK1465617T3 (da) 2009-02-16
ES2315429T3 (es) 2009-04-01
IL162469A0 (en) 2005-11-20
CN1615129A (zh) 2005-05-11
WO2003049731A1 (en) 2003-06-19
PL372326A1 (en) 2005-07-11
DE60229437D1 (de) 2008-11-27
EP1465617B1 (de) 2008-10-15
AU2002364165A1 (en) 2003-06-23
MXPA04005715A (es) 2004-10-15
JP2005511719A (ja) 2005-04-28
EP1465617A4 (de) 2005-10-12

Similar Documents

Publication Publication Date Title
DE60225651D1 (de) Verfahren zur Herstellung ionischer Metallkomplexe
EP1406639A4 (de) Verfahren zur verbesserung der wirksamkeit von krebstherapien
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
EP1501489A4 (de) Kombinationstherapie zur behandlung von krebs
TW200508201A (en) Novel process for the preparation of roflumilast
MY142988A (en) Novel aminobenzophenone compounds
BR0213424A (pt) Uso aperfeiçoado de composto antitumoral na terapia contra câncer
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
DE60307710D1 (de) Verfahren zur Herstellung von Eisenoxiden
DE602004021544D1 (de) Organische-anorganische Hybrid-Zusammensetzung für" Verfahren
DE60229959D1 (de) Kombinationstherapie zur behandlung von krebs
DE602005015174D1 (de) Verfahren zur herstellung von montelukast-natrium
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
MXPA04003755A (es) Endoprotesis vasculares.
AU2003300385A8 (en) Anticancer compounds
ATE491463T1 (de) Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
DE60229437D1 (de) Verfahren zur beeinflussung neurologischer progression
IL158184A0 (en) Anti-muc-1 single chain antibodies for tumor targeting
GB2389532B (en) The method of treating cancer
DE602004012146D1 (en) Pyrazolopyrimidine
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen
HRP20030677A2 (en) Methods of administering epothilone analogs for the treatment of cancer
DE60214629D1 (de) Verfahren zur Zersetzung von Michael-Addukten
DE60228444D1 (de) Verfahren zur herstellung von cumylphenol
TW200600084A (en) Anti-coronavirus compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1465617

Country of ref document: EP

REN Ceased due to non-payment of the annual fee